Sentynl completes asset transfer of CUTX-101 Copper Histidinate product candidate for treatment of Menkes Disease from Cyprium Read more
Non-stimulants face uphill battle to penetrate ADHD market despite lower abuse potential: GlobalData Read more
AbbVie’s $10.1 bn Immunogen deal fortifies oncology portfolio, signals big pharma’s ADC investment surge: GlobalData Read more